Zhichao Chen , Haijuan Zhang

1 Traditional Chinese Medicine Department, Longquan People's Hospital, Longquan, 323000, Zhejiang, China
2 Longquan Agricultural and Rural Bureau, Longquan, 323700, Zhejiang, China
Author    Correspondence author
Medicinal Plant Research, 2024, Vol. 14, No. 5   
Received: 02 Sep., 2024    Accepted: 05 Oct., 2024    Published: 26 Oct., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Functional beverages based on Polygonatum extract have shown great development potential in the health food market, especially for hyperglycemic management. Polygonatum species are rich in various bioactive compounds with significant pharmacological effects, such as polysaccharides, saponins, and flavonoids, which are effective in lowering blood glucose, exhibiting antioxidant properties, and regulating metabolic health. Studies have demonstrated that Polygonatum extract can effectively control blood glucose levels by regulating glucose metabolism and improving insulin sensitivity. Additionally, Polygonatum-based functional beverages have shown positive effects on other health indicators, such as improving lipid profiles, reducing body weight, and alleviating inflammation. Despite the promising results, variations in the content of active compounds due to differences in species, cultivation conditions, and extraction methods pose challenges. Moreover, the limited scale and duration of current clinical trials suggest the need for standardized extraction processes, dosage guidelines, and large-scale, long-term clinical trials in future research. By optimizing formulations and production processes, Polygonatum-based functional beverages are expected to become a natural, safe, and effective health product, providing a new management approach for hyperglycemia and other metabolic disorders.

Polygonatum extract; Functional beverage; Hyperglycemic management; Bioactive compounds; Clinical trials